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The final sample included 2,517 patients. There were 704 in the BCSRT group and 1,813 in the mastectomy group. The BCSRT group comprised 66.62% in the age group 65 -74 years, 22.30% in the age group 75 -79 years, 9.23% in the age group 80 -84 years, and 1.85% in the 85+ age group. The mastectomy group comprised 54.16% in the age group 65 -74 years, 23.88% in the age group 75 -79 years, 13.9% in the age group 80 -84 years, and 8.05% in the 85+ age group. A total of 71.44% of patients in the BCSRT group had Stage I breast cancer versus 50.91% of patients in the mastectomy group.
Study design
This was a retrospective observational study that was carried out in several centres. The study formed part of the Outcomes and Preferences for Treatment in Older Women Nationwide Survey (OPTIONS) project. Treatment assignment was based on inpatient or outpatient claims. The length of follow-up was not reported but follow-up ended in December 1997. The assessments were conducted 3 to 5 years after surgery on 1,320 of the surviving women. A regression analysis was used to input missing values.
Analysis of effectiveness
The analysis of the clinical study considered all women included in the final study sample. The outcome measures used were 5-year survival and health-state preferences. These were obtained from women interviewed in 1997 using the visual analogue scale (VAS) from the EuroQol instrument. Women in the BCSRT group were significantly more likely to be younger, have earlier-stage cancer, have lower costs before surgery, have fewer co-morbid conditions, have had BCSRT in the later years of the study period, live in areas that were more urban, be more affluent, and be more highly educated.
Effectiveness results
The estimated survival and health-state preferences were only depicted graphically. Specific values were not presented. The authors stated that slightly higher survival was associated with BCSRT treatment. Also, there was no difference in health-state preferences among survivors.
Clinical conclusions
Survival data and health-state preferences were combined in order to estimate quality-adjusted life-years (QALYs).
Measure of benefits used in the economic analysis
The summary benefit measure used was the number of QALYs. These were discounted at an annual rate of 3% because a time horizon of 5 years was considered. Three estimates of QALYs were reported. More specifically, unadjusted, adjusted using observable risk factors, and adjusted using propensity score (to control for observable confounders). For the adjusted estimate using observable risk factors, the authors used a least-squares regression and the following covariates: treatment group, age at the time of surgery, cancer stage, co-morbidity index, health care costs in the year before surgery, race, and market-area characteristics.
